

IMMUNOASSAYS AND SERVICES BIOGENIC AMINES & NEUROSCIENCE | ENDOCRINOLOGY | FOOD SAFETY

LABOR DIAGNOSTIKA NORD GmbH & Co. KG | Am Eichenhain 1 | 48531 Nordhorn | Germany | Tel. +49 5921 8197-0 | Fax +49 5921 8197-222 | info@ldn.de | www.ldn.de

Instructions for use Chromogranin A ELISA



2°C 96



Table of contents

1.	Introduction	3
1.1	Intended use and principle of the test	3
1.2	Clinical application	3
2.	Procedural cautions, guidelines, warnings and limitations	3
2.1	Procedural cautions, guidelines and warnings	3
2.2	Limitations	4
2.2.1	Interfering substances	4
2.2.2	Drug interferences	4
2.2.3	High-Dose-Hook effect	4
3.	Storage and stability	4
4.	Materials	4
4.1	Contents of the kit	4
4.2	Calibration and Controls	5
4.3	Additional materials required but not provided in the kit	5
4.4	Additional equipment required but not provided in the kit	5
5.	Sample collection, handling and storage	6
6.	Test procedure	6
6.1	Preparation of reagents and further notes	6
6.2	Preparation of samples – Dilution	6
6.3	Chromogranin A ELISA	6
7.	Calculation of results	6
7.1	Expected reference value	7
7.2	Typical standard curve	7
8.	Control samples	7
9.	Assay characteristics	7
9.1	Performance data	7
9.2	Metrological Traceability	8
10.	References/Literature	8
11.	Changes	9

1. Introduction

1.1 Intended use and principle of the test

Enzyme immunoassay for the quantitative determination of Chromogranin A in serum. The determination of Chromogranin A helps in the detection of neuroendocrine tumors and is used to assess the course of the cancer treatment.

The quantitative determination of Chromogranin A (CgA) follows the basic principles of the enzyme immunoassay. First, the Chromogranin A in the samples, controls and standards binds to CgA-specific antibodies fixed to a 96 wells microtiter plate. After incubation and following washing steps, a sandwich is formed by adding CgA antibodies conjugated to horseradish peroxidase. After incubation the wells are washed thoroughly and the complex bound to the solid phase is detected by using TMB as a substrate resulting in a colour reaction. The reaction is monitored at a wavelength of 450 nm.

By means of a standard curve the CgA concentrations in the samples are determined. Manual processing of the ELISA is recommended. The use of automatic laboratory equipment is the responsibility of the user. This in-vitro diagnostic is for professional use only.

1.2 Clinical application

Chromogranin A (CgA) is an acid glycoprotein with 439 amino acids that is present in the secretory dense core granules of most neuroendocrine cells [1]. The chromogranin family consists of at least three different water-soluble acidic glycoproteins (CgA, CgB, and secretogranin II, sometimes called Chromogranin C) [1].

Upon stimulation, CgA and other peptide hormones and neuropeptides are released. CgA is also secreted from neuroendocrine-derived tumors [1].

Neuroendocrine tumors (NETs), which originate from neuroendocrine cells, are found widely distributed throughout the body [2]. The most common sites of NET are the lung, stomach, appendix, cecum, duodenum, pancreas, jejunum/ileum, colon and rectum [3]. NET arising from the gastrointestinal tract are collectively known as gastroenteropancreatic neuroendocrine tumors (GEP-NET) and account for approximately 2/3 of incident NET [3]. The annual incidence of NET is estimated as 2 – 5 cases per 100,000 population [2].

CgA is widely expressed throughout the neuroendocrine system and serves as a general biomarker for a wide variety of neuroendocrine tumors [3]. The determination of Chromogranin A helps in the detection of neuroendocrine tumors and is used to assess the course of cancer treatment [3-6].

Therapeutic consequences should never be based on laboratory results alone, even if these results are assessed in accordance with the quality criteria of the method. Any laboratory result is only a part of the total clinical picture of the patient.

Only in cases where the laboratory results are in an acceptable agreement with the overall clinical picture of the patient, it can be used for therapeutic consequences.

2. Procedural cautions, guidelines, warnings and limitations

2.1 Procedural cautions, guidelines and warnings

- (1) This kit is intended for professional use only. Users should have a thorough understanding of this protocol for the successful use of this kit. Only the test instruction provided with the kit is valid and must be used to run the assay. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
- (2) This assay was validated for a certain type of sample as indicated in Intended Use (please refer to Chapter 1). Any off-label use of this kit is in the responsibility of the user and the manufacturer cannot be held liable.
- (3) The principles of Good Laboratory Practice (GLP) must be followed.
- (4) In order to reduce exposure to potentially harmful substances, wear lab coats, disposable protective gloves and protective glasses where necessary.
- (5) If serious incidents should occur in connection with this product, they should be reported to the manufacturer and the competent national authorities.
- (6) All kit reagents and specimens should be brought to room temperature and mixed gently but thoroughly before use. For dilution or reconstitution purposes, use deionized, distilled, or ultra-pure water. Avoid repeated freezing and thawing of reagents and specimens.
- (7) The microplate contains snap-off strips. Unused wells must be stored at 2 8 °C in the sealed foil pouch with desiccant and used in the frame provided. Microtiter strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up.
- (8) Duplicate determination of sample is highly recommended.
- (9) Once the test has been started, all steps should be completed without interruption. Make sure that the required reagents, materials, and devices are prepared for use at the appropriate time.
- (10) Incubation times do influence the results. All wells should be handled in the same order and time intervals.
- (11) To avoid cross-contamination of reagents, use new disposable pipette tips for dispensing each reagent, sample, standard and control.
- (12) A standard curve must be established for each run.
- (13) The controls should be included in each run and fall within established confidence limits. The confidence limits are listed in the QC-Report provided with the kit.
- (14) Do not mix kit components with different lot numbers within a test and do not use reagents beyond expiry date as shown on the kit labels.

Version: 23.0

- (15) Avoid contact with Stop Solution containing 0.25 M H₂SO₄. It may cause skin irritation and burns. In case of contact with eyes or skin, rinse off immediately with water.
- (16) TMB substrate has an irritant effect on skin and mucosa. In case of possible contact, wash eyes with an abundant volume of water and skin with soap and abundant water. Rinse contaminated items before reuse.
- (17) For information about hazardous substances included in the kit please refer to Safety Data Sheet (SDS). The Safety Data Sheet for this product is made available directly on the website of the manufacturer or upon request.
- (18) Kit reagents must be regarded as hazardous waste and disposed of according to national regulations.
- (19) The expected reference values reported in this test instruction are only indicative. It is recommended that each laboratory establishes its own reference intervals.
- (20) In case of any severe damage to the test kit or components, the manufacturer has to be informed in writing, at the latest, one week after receiving the kit. Severely damaged single components must not be used for a test run. They must be stored properly until the manufacturer decides what to do with them. If it is decided that they are no longer suitable for measurements, they must be disposed of in accordance with national regulations.
- (21) The results obtained with this test kit should not be taken as the sole reason for any therapeutic consequence but must be correlated to other diagnostic tests and clinical observations.
- (22) Reagents of this kit which contain human serum or plasma have been tested and confirmed negative for HIV I/II, HBsAg and HCV by approved procedures. All reagents however, should be treated as potential biohazards in use and for disposal.

2.2 Limitations

Any inappropriate handling of samples or modification of this test might influence the results.

In about 10% of the samples used in the method comparison, a discrepancy was detected between the Kryptor CgA II and the ELISA measurements. These were exclusively samples whose CgA concentrations were in the range of 350 to 900 μ g/l.

The sequence of the specific antibodies used was checked for possible cross-reactions. Even if no significant crossreactivities could be detected, it cannot be excluded that in rare individual cases and depending on medication or disease status, influences on the values may occur.

If the Chromogranin A determination is used as part of a patient's follow-up, we therefore recommend the following procedure:

- A patient's sample should always be examined using the same method during the course of his treatment.
- In case of abnormalities during the follow-up, it should be investigated whether changes in medication or lifestyle have taken place.

If you have any further questions, please contact the manufacturer.

2.2.1 Interfering substances

Serum samples containing precipitates or fibrin strands might cause inaccurate results. Biotin (up to 1,200 ng/ml), hemolytic samples (up to 1 mg/ml hemoglobin), icteric samples (up to 50 mg/dl bilirubin) and lipemic samples (up to 1,700 mg/dl triglycerides) have no influence on the assay results. When in doubt, it is recommended that hemolytic, icteric, and lipemic samples not be used in the assay.

2.2.2 Drug interferences

Medications like proton pump inhibitors, selective serotonin reuptake inhibitors, histamine type-2 receptor antagonists and somatostatin analogues can influence CgA level in serum.

2.2.3 High-Dose-Hook effect

No hook effect was observed in this test.

3. Storage and stability

Store kit and reagents at 2 - 8 °C until expiration date. Do not use kit and components beyond the expiry date indicated on the kit labels. Once opened, the reagents are stable for 2 months when stored at 2 - 8 °C. Once the resealable pouch of the ELISA plate has been opened, care should be taken to close it tightly again including the desiccant.

4. Materials

4.1 Contents of the kit

BA E-0030	WASH-CONC 50x	Wash Buffer Concentrate – concentrated 50x		
Content:	Buffer with a non-ior	Buffer with a non-ionic detergent and physiological pH		
Volume:	1 x 20 ml/vial, purple cap			
BA E-0055	SUBSTRATE	Substrate – ready to use		
Content:	Chromogenic substrate containing 3,3',5,5'-tetramethylbenzidine, substrate buffer and hydrogen peroxide			
Volume:	1 x 12 ml/vial, black	cap		

BA E-0080	STOP-SOLN	Stop Solution – ready to use			
Content:	0.25 M sulfuric acid				
Volume:	1 x 12 ml/vial, grey cap				
TM E-9010	CONJUGATE	Antibody Conjugate – ready to use			
Content:	Rabbit anti-chrom	ogranin A antibody, conjugated with peroxidase			
Volume:	1 x 6 ml/vial, red	сар			
Description:	Species is rabbit				
Hazard pictograms:					
	GHS07				
Signal word:	Warning				
Hazardous ingredients:	2-methyl-2H-isothiazol-3-one				
Hazard statements:	H317 May cause an allergic skin reaction.				
Precautionary	P280 Wear protective gloves.				
statements:	P302+P352 IF ON	SKIN: Wash with plenty of water.			
	P333+P313 If skin irritation or rash occurs: Get medical advice/attention.				
	P501 Dispose of c	ontents/container to an authorised waste collection point.			
TM E-9013	ASSAY-BUFF	Assay Buffer – ready to use			
Content:	Buffer with proteir	ns and non-mercury preservatives			
Volume:	1 x 50 ml/vial, blue cap				
Description:	Species of protein	in the buffer is bovine			
TM E-9031	Ш 96	Chromogranin A Microtiter Strips – ready to use			
Content:	1 x 96 wells (12x8) goat anti-chromogranin A antibody precoated microwell plate in a resealable pouch with desiccant				
Description:	Species is goat				

4.2 Calibration and Controls

Standards and Controls – ready to use

Cat. no.	Component	Colour/Cap	Concentration [µg/l] CgA	Volume/Vial
TM E-9001	STANDARD A	white	0	1 ml
TM E-9002	STANDARD B	yellow	30	1 ml
TM E-9003	STANDARD C	orange	110	1 ml
TM E-9004	STANDARD D	blue	450	1 ml
TM E-9005	STANDARD E	grey	900	1 ml
TM E-9051	CONTROL 1	green	Refer to QC-Report for expected	1 ml
TM E-9052	CONTROL 2	red	value and acceptable range.	1 ml
Content:	Assay Buffer wit	h a defined quanti	ty of human Chromogranin A and stabili	zing protein.

Description: Chromogranin A is derived from human, the stabilizing protein is from bovine origin.

4.3 Additional materials required but not provided in the kit

- Water (deionized, distilled, or ultra-pure)
- Absorbent material (paper towel)

4.4 Additional equipment required but not provided in the kit

- Calibrated precision pipettes to dispense volumes between 20 400 μl
- Microtiter plate washing device (manual, semi-automated or automated)
- ELISA reader capable of reading absorbance at 450 nm and if possible 620 650 nm
- Microtiter plate shaker (shaking amplitude 3 mm; approx. 600 rpm)
- Vortex mixer

5. Sample collection, handling and storage

Serum

Collect blood by venipuncture, allow to clot, and separate serum by centrifugation according to manufacturer's instructions. Do not centrifuge before complete clotting has occurred. Patients receiving anticoagulant therapy may require increased clotting time.

When in doubt, it is recommended that hemolytic, icteric, and lipemic samples not be used in the assay (see 2.2.1).

Storage: Up to 2 days at 2 - 8 °C; storage for a longer period (up to 6 months) at -20 °C. Repeated freezing and thawing should be avoided.

6. Test procedure

Allow all reagents and samples to reach room temperature and mix thoroughly by gentle inversion before use. Number the microwell plates (Microtiter Strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up). Duplicate determinations are recommended.

The binding of the antisera and of the enzyme conjugate and the activity of the enzyme are temperature dependent. The higher the temperature, the higher the absorption values will be. Varying incubation times will have similar influences on the absorbance. The optimal temperature during the enzyme immunoassay is between 20 - 25 °C.

The use of a microtiter plate shaker with the following specifications is mandatory: shaking amplitude 3 mm; approx. 600 rpm. Shaking with differing settings might influence the results.

6.1 Preparation of reagents and further notes

Wash Buffer

Dilute the 20 ml Wash Buffer Concentrate **WASH-CONC 50X** with water to a final volume of 1000 ml. Storage: 2 months at $2 - 8 \degree C$

Chromogranin A Microtiter Strips

In rare cases residues of the blocking and stabilizing reagent can be seen in the wells as small, white dots or lines. These residues do not influence the quality of the product.

6.2 Preparation of samples – Dilution

1. Prior to use, the serum samples have to be diluted **1+20** with **ASSAY-BUFF** e. g. 20 μ l of serum sample + 400 μ l of **ASSAY-BUFF**.

Serum samples which have been found off-curve should also be diluted accordingly with **ASSAY-BUFF** and re-assayed.

6.3 Chromogranin A ELISA

- 2. Discard or aspirate the content of the wells. Wash the plate 4 times by adding 300 μl of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- **3.** Pipette **50 μl** of the **CONJUGATE** into all wells and incubate **1 h** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- Discard or aspirate the content of the wells. Wash the plate 4 times by adding 300 μl of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- **5.** Pipette **100 µl** of the **SUBSTRATE** into all wells.
- 6. Incubate for 25 ± 5 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- Avoid exposure to direct sunlight!
- **7.** Add **100** µl of the **STOP-SOLN** to to all wells and shake the microtiter plate shortly.
- **8. Read** the absorbance of the solution in the wells within 10 min, using a microtiter plate reader set to **450 nm** (if available a reference wavelength between 620 nm and 650 nm is recommended).

7. Calculation of results

Moncuring range	Chromogranin A in serum	
Measuring range	2.3 – 900 μg/l	

The standard curve, which can be used to determine the concentration of the unknown samples, is obtained by plotting the absorbance readings (calculate the mean absorbance) of the standards (linear, y-axis) against the corresponding standard concentrations (logarithmic, x-axis) using a concentration of 0.001 μ g/l for Standard A (this alignment is mandatory because of the logarithmic presentation of the data). Use non-linear regression for curve fitting (e. g. 4-parameter, marquardt).

The concentrations of the samples and controls can be read directly from the standard curve. Samples found with concentrations higher than the highest standard (Standard E) should be diluted accordingly with **ASSAY-BUFF** and must be re-assayed. For the calculation of the concentrations this dilution factor has to be taken into account.


7.1 Expected reference value

It is strongly recommended that each laboratory should determine its own reference values. The expected reference values indicated below are based on method comparison studies to B·R·A·H·M·S Kryptor CqA II. The expected reference value was determined in a study by van Treijen, M.J.C., et al. [7].

	Chromogranin A in serum
Reference value (ULN)	< 100 µg/l
Typical pathological range	Up to 143,500 µg/l

7.2 Typical standard curve

Example: Do not use for calculation!



8. Control samples

It is recommended to use control samples according to national regulations. Use controls at both normal and pathological levels. Commercially obtained control samples should be treated like unknown samples. Control samples should fall within established confidence limits. The confidence limits of the kit controls are indicated on the QC-Report.

9. Assay characteristics

9.1 Performance data

Analytical Sensitivity	
Limit of Blank (LOB)	0.9 µg/l
Limit of Detection (LOD)	1.4 µg/l
Limit of Quantification (LOQ)	2.3 μg/l

Precision						
Intra-Assay n = 12			Inter-Assay n = 10			
						Sample
1	43.6 ± 1.2	2.8	1	73.0 ± 3.8	5.2	
2	73.5 ± 3.0	4.2	2	102 ± 3.5	3.5	
3	103 ± 3.4	3.3	3	161 ± 5.7	3.6	
4	161 ± 10.1	6.3	4	300 ± 16.0	5.3	
5	283 ± 14.6	5.1				
6	502 ± 15.9	3.2				

Lot-to-Lot					
	Sample	Mean ± SD [µg/I]	CV [%]		
	1	46.3 ± 2.3	5.1		
Chromogranin A in serum (n = 3)	2	111 ± 7.2	6.5		
	3	479 ± 61.8	12.9		

Recovery				
	Range [µg/l]	Mean [%]	Range [%]	
Chromogranin A	43.6 - 502	102	100 - 104	

Linearity				
	Serial Dilution up to	Mean [%]	Range [%]	
Chromogranin A	1:64	92	91 – 96	

Method Comparison: B·R·A·H·M·S Kryptor CgA II

CgA ELISA = 1.05 x (Kryptor CgA II) – 15; R² = 0.97; n = 57

Diagnostic Performance GEP-NET [7]					
Diagnostic Specificity [%]	Diagnostic Sensitivity [%]	Positive Predictive Value (PPV) [%]	Negative Predictive Value (NPV) [%]		
83	56	87	49		
Positive Likelil	nood Ratio (LR+)	Negative Likelihood Ratio (LR-)			
	3.3	0.	53		

9.2 Metrological Traceability

The values assigned to the standards and controls of the Chromogranin A ELISA are traceable to the reference method B·R·A·H·M·S Kryptor CgA II.

Standards and Controls	Uncertainty [%]
	7.5

Chromogranin A ELISA	
10.5	

* This defines an interval about the measured result that will include the true value with a probability of 95%.

10. References/Literature

- 1. O'Toole, D., et al., *ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers.* Neuroendocrinology, 2009. **90**(2): p. 194-202.
- 2. Verbeek, W.H., C.M. Korse, and M.E. Tesselaar, *GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers.* Eur J Endocrinol, 2016. **174**(1): p. R1-7.

- 3. Singh, S. and C. Law, *Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.* Expert Rev Gastroenterol Hepatol, 2012. **6**(3): p. 313-34.
- 4. Louthan, O., Chromogranin a in physiology and oncology. Folia Biol (Praha), 2011. 57(5): p. 173-81.
- 5. Yang, X., et al., *Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis.* PLoS One, 2015. **10**(4): p. e0124884.
- 6. Corti, A., F. Marcucci, and T. Bachetti, *Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.* Pflugers Arch, 2018. **470**(1): p. 199-210.
- 7. van Treijen, M.J.C., et al., *Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study.* Front Endocrinol (Lausanne), 2018. **9**: p. 740.

For updated literature or any other information please contact your local supplier. The summary of safety and performance according to article 29 of regulation (EU) 2017/746 can be downloaded from the website www.ldn.de.

11. Changes

Version	Release Date	Chapter	Change
18.0	2021-07-09	All	 Revision of the assay due to lot-change of the matched antibody pair used The IFU was revised according to the IVDR regulation (EU) 2017/746 Sample Dilution changed from 1+8 to 1+20 (Chapter 6.2) Typical pathological range was added (Chapter 7.1) Assay characteristics changed (Chapter 9.1) Lot-to-Lot and diagnostic performance was added to the assay characteristics Metrological traceability was added (Chapter 9.2) References/Literature was updated (Chapter 10)
19.0	2022-06-27	2.2.2	 Medications that can influence chromogranin level have been updated Editorial changes
20.0	2023-03-20	7.1 9.1	 More detailed description added Lot-to-Lot updated
21.0	2023-11-06	4.1 9.1	 Hazard labelling updated according to SDS Recovery updated
22.0	2024-01-02	5	 Sample storage/stability adapted
23.0	2024-08-07	4.1 7	 Hazard labelling updated according to SDS Note added to the dilution factor in the calculation

Symbols:

